Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
ACRV vs TCRX — Stock Comparison
Compare ACRV and TCRX side-by-side on StoQuant: ACRV Q-Score 47 vs TCRX 67; analyst signal 3 vs 76. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- ACRV — Acrivon Therapeutics, Inc. Common Stock · Health Care · market cap $74M · Q-Score verdict Hold (47.0, grade C) · analyst signal 3/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 93/100, ML forecast 46/100 · weakest signals: technicals 34/100, analyst consensus 0/100. Full ACRV research.
- TCRX — TScan Therapeutics, Inc. · Health Care · market cap $13M · Q-Score verdict Strong Buy (67.0, grade A) · analyst signal 76/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 99/100, analyst consensus 79/100 · weakest signals: technicals 3/100. Full TCRX research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: ACRV research · TCRX research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.